Delisted from NASDAQ in Dec 2024
RNLX - Renalytix Plc
NASDAQ
->
Healthcare
->
Diagnostics & Research
New York,
United States
Type: Equity
RNLX price evolution
RNLX
| (in millions $) | 30 Oct 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | ||||
| Current liabilities | ||||
| Accounts payable | ||||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | ||||
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | ||||
| Shareholders' equity | ||||
| Retained earnings | ||||
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 | 30 Jul 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $24.68 | $41.33 | $65.16 | $13.29 |
| Short term investments | ||||
| Net receivables | $0.78 | $0.9 | $0.59 | $0.02 |
| Inventory | $0.72 | $1.16 | $0.35 | $0.33 |
| Total current assets | $28.33 | $47.43 | $76.01 | $18.9 |
| Long term investments | ||||
| Property, plant & equipment | $1.22 | $1.72 | $1.38 | $0.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $42.12 | $63.26 | $102.58 | $41.3 |
| Current liabilities | ||||
| Accounts payable | $2.94 | $2.46 | $1.76 | $2.22 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $16.13 | $12.21 | $7.26 | $5.34 |
| Long term debt | $7.53 | $7.88 | $0.21 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $23.66 | $20.09 | $7.48 | $5.34 |
| Shareholders' equity | ||||
| Retained earnings | -$99.18 | -$52.96 | $3.77 | $34.85 |
| Other shareholder equity | $12.39 | -$1.51 | $9.7 | -$1.92 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 1 May 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.24 | |||
| Cost of revenue | ||||
| Gross Profit | -$0.05 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.7 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | |||
| Interest expense | -$3.21 | |||
| Net income | ||||
| Net income | -$23.58 | |||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 | 30 Jul 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.4 | $2.97 | $1.49 | |
| Cost of revenue | ||||
| Gross Profit | $0.7 | $0.92 | $0.69 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $43.06 | $58.29 | $33.3 | $11.08 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $7.1 | -$4.78 | -$1.36 |
| Interest expense | -$4.4 | -$1.93 | $6.92 | $0.13 |
| Net income | ||||
| Net income | -$46.22 | -$56.73 | -$31.01 | -$9.25 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.06 | -$0.69 | -$0.64 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $15.12 | -$1.61 | $25.52 | $0.26 |
| Effect of exchange rate | $0.9 | -$1.15 | -$2.9 | -$0.42 |
| Change in cash and equivalents | -$16.65 | -$17.52 | -$23.83 | -$25.23 |
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 | 30 Jul 2020 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.69 | -$0.74 | -$0.48 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $15.12 | $25.52 | $77.24 | $16.54 |
| Effect of exchange rate | $0.9 | -$2.9 | ||
| Change in cash and equivalents | -$16.65 | -$23.83 | $51.87 | $6 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |